Cdk2 and Cdk4 activities are dispensable for tumorigenesis caused by the loss of p53

Molecular and Cellular Biology

Volumn 29, Issue 10, 2009, Pages 2582-2593

  Padmakumar, V C ^a   Aleem, Eiman ^a,c   Berthet, Cyril ^a,d   Hilton, Mary Beth ^a   Kaldis, Philipp ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^c Alexandria University Faculty Of Science   (Egypt)

^d Oncodesign   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN E; PROTEIN P53; RAS PROTEIN; CDK2 PROTEIN, MOUSE; CDK4 PROTEIN, MOUSE; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CARCINOGENICITY; CELL CULTURE; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL GROWTH; CELL TRANSFORMATION; CONTROLLED STUDY; EMBRYO; EMBRYO DEVELOPMENT; EMBRYO MORTALITY; ENZYME ACTIVITY; FEMALE; FIBROBLAST; GENE CONTROL; GENE FUNCTION; GENE LOSS; GENETIC ASSOCIATION; GENOTYPE; GROWTH RATE; IN VITRO STUDY; LYMPHOBLASTOMA; MALE; MOUSE; MOUSE EMBRYO; NONHUMAN; ONCOGENE RAS; PHASE TRANSITION; PRIORITY JOURNAL; SENESCENCE; ANIMAL; CANCER TRANSPLANTATION; CELL CYCLE; CYTOLOGY; GENETICS; HUMAN; LYMPHOMA; METABOLISM; MOUSE MUTANT; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; SURVIVAL RATE;

ANIMALIA; MUS; MUS MUSCULUS;

ANIMALS; CDC2 PROTEIN KINASE; CELL CYCLE; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; FEMALE; FIBROBLASTS; HUMANS; LYMPHOMA; MALE; MICE; MICE, KNOCKOUT; MICE, NUDE; NEOPLASM TRANSPLANTATION; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 66349114807     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.00952-08     Document Type: Article

References (50)

1. Cdc2. Biochem. Biophys. Res. Commun. 283:507-512.
2. Aleem, E., H. Kiyokawa, and P. Kaldis. 2005. Cdc2-cyclin E complexes regulate the G1/S phase transition. Nat. Cell Biol. 7:831-836.
3. An, H. X., M. W. Beckmann, G. Reifenberger, H. G. Bender, and D. Niederacher. 1999. Gene amplification and overexpression of CDK4 in sporadic breast carcinomas is associated with high tumor cell proliferation. Am. J. Pathol. 154:113-118.
4. Berthet, C., E. Aleem, V. Coppola, L. Tessarollo, and P. Kaldis. 2003. Cdk2 knockout mice are viable. Curr. Biol. 13:1775-1785.
5. Berthet, C., K. D. Klarmann, M. B. Hilton, H. C. Suh, J. R. Keller, H. Kiyokawa, and P. Kaldis. 2006. Combined loss of Cdk2 and Cdk4 results in embryonic lethality and Rb hypophosphorylation. Dev. Cell 10:563-573.
6. Bianchi, A. B., S. M. Fischer, A. I. Robles, E. M. Rinchik, and C. J. Conti. 1993. Overexpression of cyclin D1 in mouse skin carcinogenesis. Oncogene 8:1127-1133.
7. cdc2 protein kinase. EMBO J. 6:3507-3517.
8. Brugarolas, J., C. Chandrasekaran, J. I. Gordon, D. Beach, T. Jacks, and G. J. Hannon. 1995. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377:552-557.
9. Kip1 CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J. 18:1571-1583.
10. Collado, M., M. A. Blasco, and M. Serrano. 2007. Cellular senescence in cancer and aging. Cell 130:223-233.
11. Dimri, G. P. 2005. What has senescence got to do with cancer? Cancer Cell 7:505-512.
12. Dimri, G. P., X. Lee, G. Basile, M. Acosta, G. Scott, C. Roskelley, E. E. Medrano, M. Linskens, I. Rubelj, O. Pereira-Smith, M. Peacocke, and J. Campisi. 1995. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl. Acad. Sci. USA 92:9363-9367.
13. Donehower, L. A., M. Harvey, B. L. Slagle, M. J. McArthur, C. A. Montgomery, Jr., J. S. Butel, and A. Bradley. 1992. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356:215-221.
14. Doumont, G., A. Martoriati, C. Beekman, S. Bogaerts, P. J. Mee, F. Bureau, E. Colombo, M. Alcalay, E. Bellefroid, F. Marchesi, E. Scanziani, P. G. Pelicci, and J. C. Marine. 2005. G1 checkpoint failure and increased tumor susceptibility in mice lacking the novel p53 target Ptprv. EMBO J. 24:3093-3103.
15. El-Deiry, W. S., T. Tokino, V. E. Velculescu, D. B. Levy, R. Parsons, J. M. Trent, D. Lin, E. Mercer, K. W. Kinzler, and B. Vogelstein. 1993. WAF1, a potent mediator of p53 tumor suppression. Cell 75:817-825.
16. Ewen, M. E., C. J. Oliver, H. K. Sluss, S. J. Miller, and D. S. Peeper. 1995. p53-dependent repression of CDK4 translation in TGF-beta-induced G1 cell-cycle arrest. Genes Dev. 9:204-217.
17. Hartwell, L. H., and M. B. Kastan. 1994. Cell cycle control and cancer. Science 266:1821-1828.
18. He, G., Z. H. Siddik, Z. Huang, R. Wang, J. Koomen, R. Kobayashi, A. R. Khokhar, and J. Kuang. 2005. Induction of p21 by p53 following DNA damage inhibits both Cdk4 and Cdk2 activities. Oncogene 24:2929-2943.
19. Hinds, P., C. Finlay, and A. J. Levine. 1989. Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation. J. Virol. 63:739-746.
20. Iida, H., M. Towatari, M. Tanimoto, Y. Morishita, Y. Kodera, and H. Saito. 1997. Overexpression of cyclin E in acute myelogenous leukemia. Blood 90:3707-3713.
21. 2/M promoters. Mol. Cell. Biol. 25:3737-3751.
22. Jacks, T., L. Remington, B. O. Williams, E. M. Schmitt, S. Halachmi, R. T. Bronson, and R. A. Weinberg. 1994. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 4:1-7.
23. Kim, W. Y., and N. E. Sharpless. 2006. The regulation of INK4/ARF in cancer and aging. Cell 127:265-275.
24. Kohn, K. W., J. Jackman, and P. M. O'Connor. 1994. Cell cycle control and cancer chemotherapy. J. Cell. Biochem. 54:440-452.
25. Lantsov, D., S. Meirmanov, M. Nakashima, H. Kondo, V. Saenko, Y. Naruke, H. Namba, M. Ito, A. Abrosimov, E. Lushnikov, I. Sekine, and S. Yamashita. 2005. Cyclin D1 overexpression in thyroid papillary microcarcinoma: its association with tumour size and aberrant beta-catenin expression. Histopathology 47:248-256.
26. Levy, N., E. Yonish-Rouach, M. Oren, and A. Kimchi. 1993. Complementation by wild-type p53 of interleukin-6 effects on M1 cells: induction of cell cycle exit and cooperativity with c-myc suppression. Mol. Cell. Biol. 13:7942-7952.
27. Li, W., S. Kotoshiba, C. Berthet, M. B. Hilton, and P. Kaldis. 2009. Rb/Cdk2/Cdk4 triple mutant mice elicit an alternative mechanism for regulation of the G1/S transition. Proc. Natl. Acad. Sci. USA 106:486-491.
28. Li, Y., C. W. Jenkins, M. A. Nichols, and Y. Xiong. 1994. Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21. Oncogene 9:2261-2268.
29. Marone, M., G. Scambia, C. Giannitelli, G. Ferrandina, V. Masciullo, A. Bellacosa, P. Benedetti-Panici, and S. Mancuso. 1998. Analysis of cyclin E and CDK2 in ovarian cancer: gene amplification and RNA overexpression. Int. J. Cancer 75:34-39.
30. Miller, J. J., M. K. Summers, D. V. Hansen, M. V. Nachury, N. L. Lehman, A. Loktev, and P. K. Jackson. 2006. Emi1 stably binds and inhibits the anaphase-promoting complex/cyclosome as a pseudosubstrate inhibitor. Genes Dev. 20:2410-2420.
31. Ortega, S., I. Prieto, J. Odajima, A. Martin, P. Dubus, R. Sotillo, J. L. Barbero, M. Malumbres, and M. Barbacid. 2003. Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat. Genet. 35:25-31.
32. Rane, S. G., P. Dubus, R. V. Mettus, E. J. Galbreath, G. Boden, E. P. Reddy, and M. Barbacid. 1999. Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in β-islet cell hyperplasia. Nat. Genet. 22:44-52.
33. Reimann, J. D., E. Freed, J. Y. Hsu, E. R. Kramer, J. M. Peters, and P. K. Jackson. 2001. Emi1 is a mitotic regulator that interacts with Cdc20 and inhibits the anaphase promoting complex. Cell 105:645-655.
34. Sachdeva, M., S. Zhu, F. Wu, H. Wu, V. Walia, S. Kumar, R. Elble, K. Watabe, and Y. Y. Mo. 2009. p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc. Natl. Acad. Sci. USA 106:3207-3212.
35. Satyanarayana, A., M. B. Hilton, and P. Kaldis. 2008. p21 inhibits Cdk1 in the absence of Cdk2 to maintain the G1/S phase DNA damage checkpoint. Mol. Biol. Cell 19:65-77.
36. Scuderi, R., K. A. Palucka, K. Pokrovskaja, M. Bjorkholm, K. G. Wiman, and P. Pisa. 1996. Cyclin E overexpression in relapsed adult acute lymphoblastic leukemias of B-cell lineage. Blood 87:3360-3367.
37. Sherr, C. J., and R. A. DePinho. 2000. Cellular senescence: mitotic clock or culture shock? Cell 102:407-410.
38. Sherr, C. J., and J. M. Roberts. 1999. Cdk inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13:1501-1512.
39. Taylor, W. R., S. E. Egan, M. Mowat, A. H. Greenberg, and J. A. Wright. 1992. Evidence for synergistic interactions between ras, myc and a mutant form of p53 in cellular transformation and tumor dissemination. Oncogene 7:1383-1390.
40. Todaro, G. J., and H. Green. 1963. Quantitative studies of the growth of mouse embryo cells in culture and their development into established lines. J. Cell Biol. 17:299-313.
41. Truett, G. E., P. Heeger, R. L. Mynatt, A. A. Truett, J. A. Walker, and M. L. Warman. 2000. Preparation of PCR-quality mouse genomic DNA with hot sodium hydroxide and tris (HotSHOT). BioTechniques 29:52-54.
42. Kip1 activity. Mol. Cell. Biol. 19:7011-7019.
43. Waldman, T., K. W. Kinzler, and B. Vogelstein. 1995. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res. 55:5187-5190.
44. ARF tumor suppressor. Genes Dev. 14:2358-2365.
45. Wunder, J. S., K. Eppert, S. R. Burrow, N. Gokgoz, R. S. Bell, and I. L. Andrulis. 1999. Co-amplification and overexpression of CDK4, SAS and MDM2 occurs frequently in human parosteal osteosarcomas. Oncogene 18:783-788.
46. Yu, Q., Y. Geng, and P. Sicinski. 2001. Specific protection against breast cancers by cyclin D1 ablation. Nature 411:1017-1021.
47. Yu, Q., E. Sicinska, Y. Geng, M. Ahnstrom, A. Zagozdzon, Y. Kong, H. Gardner, H. Kiyokawa, L. N. Harris, O. Stal, and P. Sicinski. 2006. Requirement for CDK4 kinase function in breast cancer. Cancer Cell 9:23-32.
48. Yun, J., H. D. Chae, H. E. Choy, J. Chung, H. S. Yoo, M. H. Han, and D. Y. Shin. 1999. p53 negatively regulates cdc2 transcription via the CCAAT-binding NF-Y transcription factor. J. Biol. Chem. 274:29677-29682.
49. Zambetti, G. P., D. Olson, M. Labow, and A. J. Levine. 1992. A mutant p53 protein is required for maintenance of the transformed phenotype in cells transformed with p53 plus ras cDNAs. Proc. Natl. Acad. Sci. USA 89:3952-3956.
50. Zou, X., D. Ray, A. Aziyu, K. Christov, A. D. Boiko, A. V. Gudkov, and H. Kiyokawa. 2002. Cdk4 disruption renders primary mouse cells resistant to oncogenic transformation, leading to Arf/p53-independent senescence. Genes Dev. 16:2923-2934.